Roubaix Capital LLC Takes $1.85 Million Position in Omnicell, Inc. (NASDAQ:OMCL)

Roubaix Capital LLC bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 42,461 shares of the company’s stock, valued at approximately $1,851,000.

A number of other institutional investors have also made changes to their positions in the business. Federated Hermes Inc. increased its holdings in shares of Omnicell by 1,113.6% in the second quarter. Federated Hermes Inc. now owns 991,151 shares of the company’s stock valued at $26,830,000 after purchasing an additional 909,480 shares during the last quarter. Pacer Advisors Inc. raised its holdings in Omnicell by 32.6% in the 2nd quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock valued at $56,047,000 after acquiring an additional 508,789 shares during the period. Vanguard Group Inc. raised its holdings in Omnicell by 8.5% in the 4th quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock valued at $209,653,000 after acquiring an additional 434,336 shares during the period. Champlain Investment Partners LLC lifted its position in Omnicell by 16.0% during the first quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock worth $51,246,000 after acquiring an additional 241,235 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Omnicell by 61.3% during the second quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock worth $16,240,000 after acquiring an additional 228,093 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Up 32.2 %

OMCL stock opened at $53.05 on Thursday. The company has a market cap of $2.44 billion, a PE ratio of -115.33, a price-to-earnings-growth ratio of 43.55 and a beta of 0.83. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. Omnicell, Inc. has a 52 week low of $25.12 and a 52 week high of $55.74. The business has a 50-day simple moving average of $43.14 and a 200 day simple moving average of $35.07.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, topping analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. The firm’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.29 EPS. Sell-side analysts anticipate that Omnicell, Inc. will post 0.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OMCL has been the topic of a number of recent research reports. Barclays upgraded Omnicell from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $26.00 to $39.00 in a research note on Friday, August 2nd. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research report on Saturday, October 19th. Bank of America boosted their target price on shares of Omnicell from $34.00 to $44.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company raised their price target on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research note on Friday, August 23rd. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus price target of $41.33.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.